mRNA in cancer immunotherapy: beyond a source of antigen

被引：0

作者：

Lien Van Hoecke

Rein Verbeke

Heleen Dewitte

Ine Lentacker

Karim Vermaelen

Karine Breckpot

Sandra Van Lint

机构：

[1] VIB-UGent Center for Inflammation Research,Department of Biomedical Molecular Biology

[2] Ghent University,Ghent Research Group on Nanomedicines, Lab for General Biochemistry and Physical Pharmacy, Department of Pharmaceutical Sciences

[3] Ghent University,Cancer Research Institute Ghent (CRIG)

[4] Ghent University,Tumor Immunology Laboratory, Department of Respiratory Medicine and Immuno

[5] Ghent University Hospital,Oncology Network Ghent

[6] Vrije Universiteit Brussel,Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences

来源：

Molecular Cancer | / 20卷

关键词：

Cancer; mRNA; Nanoparticle; Antibody; Dendritic cell; T cell; Cytokine; Tumor microenvironment;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

mRNA therapeutics have become the focus of molecular medicine research. Various mRNA applications have reached major milestones at high speed in the immuno-oncology field. This can be attributed to the knowledge that mRNA is one of nature’s core building blocks carrying important information and can be considered as a powerful vector for delivery of therapeutic proteins to the patient.

引用

共 50 条

[31] The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy
Dewitte, Heleen
Van Lint, Sandra
Heirman, Carlo
Thielemans, Kris
De Smedt, Stefaan C.
Breckpot, Karine
Lentacker, Ine
JOURNAL OF CONTROLLED RELEASE, 2014, 194 : 28 - 36
[32] Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA
Morse, MA
Nair, SK
Mosca, PJ
Hobeika, AC
Clay, TM
Deng, YP
Boczkowski, D
Proia, A
Neidzwiecki, D
Clavien, PA
Hurwitz, HI
Schlom, J
Gilboa, E
Lyerly, HK
CANCER INVESTIGATION, 2003, 21 (03) : 341 - 349
[33] Plasma cell lysate as an antigen source in multiple myeloma immunotherapy
Ritchie, David S.
LEUKEMIA & LYMPHOMA, 2007, 48 (10) : 1894 - 1895
[34] IL-2 and Beyond in Cancer Immunotherapy
Wrangle, John M.
Patterson, Alicia
Johnson, C. Bryce
Neitzke, Daniel J.
Mehrotra, Shikhar
Denlinger, Chadrick E.
Paulos, Chrystal M.
Li, Zihai
Cole, David J.
Rubinstein, Mark P.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2018, 38 (02): : 45 - 68
[35] Cancer immunotherapy beyond immune checkpoint inhibitors
Julian A. Marin-Acevedo
Aixa E. Soyano
Bhagirathbhai Dholaria
Keith L. Knutson
Yanyan Lou
Journal of Hematology & Oncology, 11
[36] Cancer Immunotherapy: Sipuleucel-T and Beyond
Hammerstrom, Aimee E.
Cauley, Diana H.
Atkinson, Bradley J.
Sharma, Padmanee
PHARMACOTHERAPY, 2011, 31 (08): : 813 - 828
[37] Cancer immunotherapy beyond immune checkpoint inhibitors
Marin-Acevedo, Julian A.
Soyano, Aixa E.
Dholaria, Bhagirathbhai
Knutson, Keith L.
Lou, Yanyan
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[38] Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer
Silvestri, Ida
Cattarino, Susanna
Agliano, Anna Maria
Collalti, Giulia
Sciarra, Alessandro
BIOMED RESEARCH INTERNATIONAL, 2015, 2015
[39] Antigen-specific immunotherapy and cancer vaccines
Jäger, E
Jäger, D
Knuth, A
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (06) : 817 - 820
[40] Biomaterials as Antigen Delivery Carrier for Cancer Immunotherapy
Wooram Um
Anuradha Gupta
Seok Ho Song
Chan Ho Kim
Jae Hyung Park
Macromolecular Research, 2021, 29 : 834 - 842

← 1 2 3 4 5 →